Payment & Shipping Terms:
|Appearance:||White Or Off-white Powder||Formula:||C7H11N3O6S|
|Molar Mass:||265.24 G/mol||Storage:||Store The Shade|
active pharmaceutical ingredients,
bulk drug intermediates
|Trade names||Avycaz (formulated with ceftazidime)|
|Onset of action||Increases in proportion to dose|
|Chemical and physical data|
|Molar mass||265.24 g/mol|
|3D model (JSmol)|
Avibactam is a non-β-lactam β-lactamase inhibitor developed by Actavis (now [Teva]) jointly with AstraZeneca. A new drug application for avibactam in combination with ceftazidime (branded as Avycaz) was approved by the FDA on February 25, 2015, for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant Gram-negative bacterial pathogens.
Increasing resistance to cephalosporins among Gram-(−) bacterial pathogens, especially among hospital-acquired infections, results in part from the production of β-lactamase enzymes that deactivate these antibiotics. While the co-administration of a β-lactamase inhibitor can restore antibacterial activity to the cephalosporin, previously approved β-lactamase inhibitors such as tazobactam andclavulanic acid do not inhibit important classes of β-lactamases, including Klebsiella pneumoniae carbapenemases (KPCs), New Delhi metallo-β-lactamase 1 (NDM-1), and AmpC-type β-lactamases. Whilst avibactam inhibits class A (KPCs, CTX-M, TEM, SHV), class C (AmpC), and, some, class D serine β-lactamases (such as OXA-23, OXA-48), it has been reported to be a poor substrate/weak inhibitor of class B metallo-β-lactamases, such as VIM-2, VIM-4, SPM-1, BcII, NDM-1, Fez-1.
Contact Person: admin